# Drugs Made In America Acquisition II Corp. (DMII) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Financial Services / Diversified Financial Services. Price $10.17, market value $648 million.

## Valuation
- **P/E (trailing): 35.1×**. Drugs Made In America Acquisition II Corp. trades at 35.1× trailing earnings. The Financial Services median in the September 2026 study was 13.1×.
- **Earnings yield: 2.9%**. The inverse of the P/E: 2.9% of the price is earned each year.

## Profitability
- **Return on equity: -23.6%**. Return on equity is negative because earnings are negative.

## Dividends
- **Dividend: none**. Drugs Made In America Acquisition II Corp. does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -0.4%** (3.1% above the low). Trading within 5% of its 52-week high.
- **RSI (14-day): 70**. An RSI of 70 is neutral.
- **Beta (1 yr): -0.01** (volatility 2%). Beta of -0.01 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DMII · Page: https://foliofundamentals.com/stocks/dmii

Not investment advice.